List view / Grid view
13 July 2016 | By Victoria White, Digital Content Producer
Prevnar 13 is now approved for adults 18 years of age and older for the prevention of pneumococcal pneumonia and invasive disease caused by S. pneumoniae...
11 July 2016 | By Victoria White, Digital Content Producer
The SMC has accepted five new medicines for routine use in NHS Scotland including lung cancer treatments nivolumab and crizotinib...
8 July 2016 | By Victoria White, Digital Content Producer
The S-TRAC study of Sutent versus placebo in the adjuvant setting met its primary endpoint of improving disease-free survival in renal cell carcinoma...
7 July 2016 | By Victoria White, Digital Content Producer
Bosutinib is the first drug to go through the reappraisal process, where NICE assesses the cost and clinical effectiveness of drugs currently in the old CDF...
6 July 2016 | By Victoria White, Digital Content Producer
Avelumab will be evaluated in combination with, and/or as follow-on treatment to, platinum-based chemotherapy in patients with epithelial ovarian cancer...
28 June 2016 | By Victoria White, Digital Content Producer
Two Phase III trials of Pfizer’s bococizumab, SPIRE-HR (HighRisk) and SPIRE-FH (Familial Hypercholesterolemia), met their primary endpoint...
28 June 2016 | By Victoria White, Digital Content Producer
Pfizer is to invest $350 million in the development of a state-of-the-art Global Biotechnology Centre in the Hangzhou Economic Development Area...
The Anacor acquisition adds crisaborole, a differentiated non-steroidal topical PDE4 inhibitor with anti-inflammatory properties, to Pfizer's pipeline...
21 June 2016 | By Victoria White, Digital Content Producer
The Phase I study will evaluate the ability of UCART19 to induce molecular remission in paediatric patients with relapsed or refractory CD19 positive B-ALL...
17 June 2016 | By Victoria White, Digital Content Producer
Pfizer will invest more than $200 million in the development of the state-of-the-art facility that will enable the production of high-quality, complex biologics...
14 June 2016 | By Victoria White, Digital Content Producer
PF-00547659 is an investigational biologic being evaluated for the treatment of moderate-to-severe inflammatory bowel disease (IBD)...
14 June 2016 | By Victoria White, Digital Content Producer
Two studies of ertugliflozin, an investigational oral SGLT-2 inhibitor for the treatment of patients with type 2 diabetes, met their primary endpoints...
13 June 2016 | By Victoria White, Digital Content Producer
Results showed improvement over chemotherapy on a number of measures including complete haematologic remission and progression-free survival...
8 June 2016 | By Victoria White, Digital Content Producer
The OPAL Beyond study met its primary efficacy endpoints demonstrating a statistically significant improvement with tofacitinib 5 mg BID and 10 mg BID...
24 May 2016 | By Victoria White, Digital Content Producer
As part of the update, the black triangle symbol, indicating that additional safety monitoring for Champix in the UK was required, has been removed...
